High-yield expression, purification and characterization of tumor-targeted IFN-α2a

Cytotherapy

Volumn 9, Issue 1, 2007, Pages 60-68

  Meng, J ^a,b   Yan, Z ^a,b   Xue, X ^a,b   Hao, Q ^a,b   Wan, Y ^a,b   Qin, X ^a,b   Zhang, C ^a,b   You, Y ^a,b   Han, W ^a,b   Zhang, Y ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b State Key Laboratory of Cancer Biology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ARGINYLGLYCYLASPARTIC ACID; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; HYBRID PROTEIN; OLIGOPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PURITY; DRUG SELECTIVITY; DRUG TARGETING; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ION EXCHANGE CHROMATOGRAPHY; LOW DRUG DOSE; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CELL MOTION; CONFOCAL MICROSCOPY; CYTOLOGY; DRUG EFFECT; DRUG SCREENING; ENDOTHELIUM CELL; EPITHELIUM CELL; GENE EXPRESSION; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; NEOPLASM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENDOTHELIAL CELLS; EPITHELIAL CELLS; ESCHERICHIA COLI; GENE EXPRESSION; HUMANS; INTERFERON-ALPHA; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, CONFOCAL; NEOPLASMS; OLIGOPEPTIDES; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34247177587     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240601094322     Document Type: Article

References (24)

1. Petska, S., Langer, JA and Zoon, KC (1987) Interferons and their actions. Annu Rev Biochem, 56, pp. 727-777.
2. Sliver, RT, Woolf, SH and Hehlmann, R. (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and alloeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology. Blood, 94, pp. 1517-1536.
3. Gutterman, JU. (1994) Cytokine therapeutics: Lessons from interferon-α. Proc Natl Acad Sci USA, 91, pp. 1198-1205.
4. Wadler, S. (1992) The role of interferons in the treatment of solid tumors. Cancer, 70, pp. 949-958.
5. Motzer, RJ, Murphy, BA and Bacik, J. (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol, 16, pp. 2972-2980.
6. Caraceni, A., Gangeri, L. and Martini, C. (1998) Neurotoxicity of interferon alfa in melanoma therapy: Results from a randomized controlled trial. Cancer, 83, pp. 482-489.
7. Yamada, S., Takada, K. and Tsuchida, S. (1996) A study of anterior pituitary hormone secretion in patients with glioma receiving interferon-beta treatment. Endocr J, 43, pp. 335-338.
8. Arap, W., Pasqualini, R. and Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279, pp. 377-380.
9. Sacchi, A., Gasparri, A. and Curnis, F. (2004) Crucial role for interferon γ in the synergism between tumor vasculature-targeted tumor necrosis factor α (NGR-TNF) and doxorubicin. Cancer Res, 64, pp. 7150-7155.
10. Hölig, P., Bach, M. and Volkel, T. (2004) Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng Des Sel, 17, pp. 433-441.
11. Wang, H., Yan, Z. and Shi, J. (2006) Expression, purification, and characterization of a neovasculature targeted rmhTNF-α in Escherichia coli. Protein Exp Purif, 45, pp. 60-65.
12. Pasqualini, R., Koivunen, E. and Kain, R. (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res, 60, pp. 722-727.
13. Shipp, MA and Look, AT. (1993) Hematopoietic differentiation antigens that are membrane-associated enzymes: Cutting is the key!. Blood, 82, pp. 1052-1070.
14. Curnis, F., Arrigoni, G. and Sacchi, A. (2002) Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia and myeloid cells. Cancer Res, 62, pp. 867-874.
15. Rubinstein, S., Familletti, PC and Pestka, S. (1981) Convenient assay for interferons. J Virol, 37, pp. 755-758.
16. Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, p. 353.
17. Carmeliet, P. and Jain, RK. (2000) Angiogenesis in cancer and other diseases. Nature, 407, pp. 249-257.
18. Rios, A., Mansell, PW and Newell, GR (1985) Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon. J Clin Oncol, 5, pp. 506-512.
19. Sidky, YA, Borden, EC and Borden, EC. (1987) Inhibition of angiogenesis by interferon: Effects on tumor and lymphocyte inducted vascular responses. Cancer Res, 47, pp. 5155-5161.
20. Gaudin, PB and Rosai, J. (1995) Florid vascular proliferation associated with neural and neuroendocrine neoplasms. A diagnostic clue and potential pitfall. Am J Surg Pathol, 19, pp. 642-652.
21. von Marschall, Z., Scholz, A. and Cramer, T. (2003) Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst, 95, pp. 437-448.
22. 3 integrin binding peptieds in a nude mouse model. Cancer Res, 62, pp. 6146-6151.
23. Chen, Y. and Hong, S. (2001) RGD-tachyplesin inhibits tumor growth. Cancer Res, 61, pp. 2434-2438.
24. Bhagwat, SV, Lahdenranta, J. and Giordano, R. (2001) CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood, 97, pp. 652-659.